Serum amyloid A: A potential biomarker of lung disorders.
Acute-phase protein
Lung diseases
Prognosis
Serum amyloid A
Serum biomarkers
Journal
Respiratory investigation
ISSN: 2212-5353
Titre abrégé: Respir Investig
Pays: Netherlands
ID NLM: 101581124
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
01
07
2019
revised:
29
08
2019
accepted:
20
09
2019
pubmed:
12
11
2019
medline:
5
8
2020
entrez:
12
11
2019
Statut:
ppublish
Résumé
Serum amyloid A is an acute-phase protein with multiple immunological functions. Serum amyloid A is involved in lipid metabolism, inflammatory reactions, granuloma formation, and cancerogenesis. Additionally, serum amyloid A is involved in the pathogenesis of different autoimmune lung diseases. The levels of serum amyloid A has been evaluated in biological fluids of patients with different lung diseases, including autoimmune disorders, chronic obstructive pulmonary diseases, obstructive sleep apnea syndrome, sarcoidosis, asthma, lung cancer, and other lung disorders, such as idiopathic pulmonary fibrosis, tuberculosis, radiation pneumonitis, and cystic fibrosis. This review focuses on the cellular and molecular interactions of serum amyloid A in different lung diseases and suggests this acute-phase protein as a prognostic marker.
Identifiants
pubmed: 31708467
pii: S2212-5345(19)30165-0
doi: 10.1016/j.resinv.2019.09.005
pii:
doi:
Substances chimiques
Amyloid
0
Biomarkers
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
21-27Informations de copyright
Copyright © 2019 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.